Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Submitted by
admin
on July 19, 2017 - 9:28am
Source:
Endpoints
News Tags:
Eli Lilly
R&D
antibodies
Adimab
Headline:
Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Do Not Allow Advertisers to Use My Personal information
